Baseline characteristics of older (age 50 years or above) patients who received PTCy-based GVHD prophylaxis
| . | Older MSD . | Young MUD . | Young haplo donor . | Young MMUD . | P value . | Total . |
|---|---|---|---|---|---|---|
| No. of patients | 540 | 1221 | 1518 | 467 | 3746 | |
| Patient characteristics | ||||||
| Patient age, y | <.01† | |||||
| Mean (SD) | 62.1 (5.85) | 64.7 (6.30) | 60.9 (5.82) | 62.7 (6.45) | 62.5 (6.28) | |
| Sex, n (%) | <.01∗ | |||||
| Male | 311 (57.6) | 769 (63.0) | 994 (65.5) | 222 (47.5) | 2296 (61.3) | |
| Female | 229 (42.4) | 452 (37.0) | 524 (34.5) | 245 (52.5) | 1450 (38.7) | |
| Karnofsky score, n (%) | .57∗ | |||||
| <90 | 262 (48.5) | 583 (47.7) | 730 (48.1) | 230 (49.3) | 1805 (48.2) | |
| Race/ethnicity, n (%) | <.01∗ | |||||
| Asian | 26 (4.8) | 22 (1.8) | 118 (7.8) | 18 (3.9) | 184 (4.9) | |
| Black | 40 (7.4) | 18 (1.5) | 207 (13.6) | 50 (10.7) | 315 (8.4) | |
| White, non-Hispanic | 382 (70.7) | 1083 (88.7) | 915 (60.3) | 328 (70.2) | 2708 (72.3) | |
| White, Hispanic | 38 (7.0) | 37 (3.0) | 170 (11.2) | 44 (9.4) | 289 (7.7) | |
| Unknown/other‡ | 54 (10) | 61 (5.0) | 108 (7.1) | 27 (5.8) | 250 (6.7) | |
| HCT-CI, n (%) | .20∗ | |||||
| ≥3 | 281 (52.0) | 670 (54.9) | 774 (51.0) | 263 (56.3) | 1988 (53.1) | |
| Donor characteristics | ||||||
| Donor age, y | <.01† | |||||
| Mean (SD) | 60.2 (5.65) | 26.2 (4.14) | 28.1 (4.50) | 26.5 (4.02) | 31.9 (12.5) | |
| Donor sex, n (%) | <.01∗ | |||||
| Male | 283 (52.4) | 822 (67.3) | 947 (62.4) | 261 (55.9) | 2313 (61.7) | |
| Female | 257 (47.6) | 399 (32.7) | 571 (37.6) | 206 (44.1) | 1433 (38.3) | |
| Donor/recipient CMV serostatus n (%) | <.01∗ | |||||
| +/+ | 249 (46.1) | 335 (27.4) | 563 (37.1) | 143 (30.6) | 1290 (34.4) | |
| +/− | 56 (10.4) | 117 (9.6) | 81 (5.3) | 72 (15.4) | 326 (8.7) | |
| −/+ | 118 (21.9) | 416 (34.1) | 475 (31.3) | 143 (30.6) | 1152 (30.8) | |
| −/− | 110 (20.4) | 348 (28.5) | 390 (25.7) | 109 (23.3) | 957 (25.5) | |
| Not reported | 7 (1.3) | 5 (0.4) | 9 (0.6) | 0 (0.0) | 21 (0.6) | |
| Disease characteristics | ||||||
| Primary disease, n (%) | <.01∗ | |||||
| AML | 329 (60.9) | 662 (54.2) | 857 (56.5) | 283 (60.6) | 2131 (56.9) | |
| ALL | 50 (9.3) | 119 (9.7) | 211 (13.9) | 61 (13.1) | 441 (11.8) | |
| MDS | 161 (29.8) | 440 (36.0) | 450 (29.6) | 123 (26.3) | 1174 (31.3) | |
| AML: ELN 2017 risk, n (%) | <.01∗ | |||||
| Normal | 51 (15.5) | 105 (15.9) | 154 (18.0) | 41 (14.5) | 351 (16.5) | |
| Favorable | 26 (7.9) | 86 (13.0) | 118 (13.8) | 20 (7.1) | 250 (11.7) | |
| Intermediate | 111 (33.7) | 164 (24.8) | 227 (26.5) | 73 (25.8) | 575 (27.0) | |
| Poor | 128 (38.9) | 296 (44.7) | 341 (39.8) | 143 (50.5) | 908 (42.6) | |
| APL | 0 (0.0) | 2 (0.3) | 3 (0.4) | 1 (0.4) | 6 (0.3) | |
| Not reported | 13 (4.0) | 9 (1.4) | 14 (1.6) | 5 (1.8) | 41 (1.9) | |
| ALL: cytogenetics, n (%) | .77∗ | |||||
| Normal | 6 (12.0) | 23 (19.3) | 45 (21.3) | 8 (13.1) | 82 (18.6) | |
| Poor | 37 (74.0) | 80 (67.2) | 131 (62.1) | 44 (72.1) | 292 (66.2) | |
| Other | 4 (8.0) | 12 (10.1) | 23 (10.9) | 6 (9.8) | 45 (10.2) | |
| Not reported | 3 (6.0) | 4 (3.4) | 12 (5.7) | 3 (4.9) | 22 (5.0) | |
| MDS: IPSS-R, n (%) | .55∗ | |||||
| Very low | 3 (1.9) | 8 (1.8) | 5 (1.1) | 1 (0.8) | 17 (1.4) | |
| Low | 110 (68.3) | 276 (62.7) | 287 (63.8) | 79 (64.2) | 752 (64.1) | |
| Intermediate | 11 (6.8) | 33 (7.5) | 49 (10.9) | 12 (9.8) | 105 (8.9) | |
| High | 5 (3.1) | 11 (2.5) | 16 (3.6) | 5 (4.1) | 37 (3.2) | |
| Very high | 28 (17.4) | 108 (24.5) | 88 (19.6) | 25 (20.3) | 249 (21.2) | |
| Not reported | 4 (2.5) | 4 (0.9) | 5 (1.1) | 1 (0.8) | 14 (1.2) | |
| Leukemia remission status, n (%) | <.01∗ | |||||
| First complete remission | 268 (70.7) | 613 (78.5) | 787 (73.7) | 260 (75.6) | 1928 (75.0) | |
| Second complete remission | 52 (13.7) | 79 (10.1) | 152 (14.2) | 45 (13.1) | 328 (12.8) | |
| Primary induction failure | 37 (9.8) | 61 (7.8) | 98 (9.2) | 24 (7.0) | 220 (8.6) | |
| Other§ | 22 (5.8) | 28 (3.6) | 31 (3) | 15 (4.4) | 96 (3.6) | |
| MDS remission status, n (%) | .08∗ | |||||
| No response/stable disease | 101 (62.7) | 267 (60.7) | 293 (65.1) | 65 (52.8) | 726 (61.8) | |
| Hematologic improvement | 25 (15.5) | 80 (18.2) | 69 (15.3) | 23 (18.7) | 197 (16.8) | |
| Complete remission | 25 (15.5) | 73 (16.6) | 64 (14.2) | 26 (21.1) | 188 (16.0) | |
| Other|| | 10 (6.2) | 20 (4.5) | 24 (5.4) | 9 (7.3) | 63 (5.4) | |
| Transplant characteristics | ||||||
| Graft type, n (%) | <.01∗ | |||||
| Bone marrow | 57 (10.6) | 115 (9.4) | 322 (21.2) | 79 (16.9) | 573 (15.3) | |
| Peripheral blood | 483 (89.4) | 1106 (90.6) | 1196 (78.8) | 388 (83.1) | 3173 (84.7) | |
| Time from diagnosis to transplant, d | <.01† | |||||
| Median (25-75 percentile) | 162 (113-294) | 186 (136-293) | 188 (133-323) | 199 (144-337) | 186 (133-312) | |
| GVHD prophylaxis, n (%) | <.01∗ | |||||
| PTCy + other(s) | 499 (92.4) | 1178 (96.5) | 1516 (99.9) | 464 (99.4) | 3657 (97.6) | |
| PTCy alone | 41 (7.6) | 43 (3.5) | 2 (0.1) | 3 (0.6) | 89 (2.4) | |
| Conditioning regimen intensity, n (%) | <.01∗ | |||||
| Myeloablative | 242 (44.8) | 438 (35.9) | 457 (30.1) | 136 (29.1) | 1273 (34.0) | |
| Reduced intensity | 206 (38.1) | 614 (50.3) | 396 (26.1) | 203 (43.5) | 1419 (37.9) | |
| Nonmyeloablative | 92 (17.0) | 168 (13.8) | 665 (43.8) | 127 (27.2) | 1052 (28.1) | |
| Unknown | 0 (0.0) | 1 (0.1) | 0 (0.0) | 1 (0.2) | 2 (<0.1) | |
| Transplant years, n (%) | <.01∗ | |||||
| 2014-2017 | 175 (32.4) | 175 (14.3) | 415 (27.3) | 80 (17.1) | 845 (22.6) | |
| 2018-2021 | 365 (67.6) | 1046 (85.7) | 1103 (72.7) | 387 (82.9) | 2901 (77.4) | |
| Follow-up of survivors, median (range), mo | 36 (3-101) | 26 (3-100) | 36 (3-104) | 27 (3-89) | 36 (3-104) |
| . | Older MSD . | Young MUD . | Young haplo donor . | Young MMUD . | P value . | Total . |
|---|---|---|---|---|---|---|
| No. of patients | 540 | 1221 | 1518 | 467 | 3746 | |
| Patient characteristics | ||||||
| Patient age, y | <.01† | |||||
| Mean (SD) | 62.1 (5.85) | 64.7 (6.30) | 60.9 (5.82) | 62.7 (6.45) | 62.5 (6.28) | |
| Sex, n (%) | <.01∗ | |||||
| Male | 311 (57.6) | 769 (63.0) | 994 (65.5) | 222 (47.5) | 2296 (61.3) | |
| Female | 229 (42.4) | 452 (37.0) | 524 (34.5) | 245 (52.5) | 1450 (38.7) | |
| Karnofsky score, n (%) | .57∗ | |||||
| <90 | 262 (48.5) | 583 (47.7) | 730 (48.1) | 230 (49.3) | 1805 (48.2) | |
| Race/ethnicity, n (%) | <.01∗ | |||||
| Asian | 26 (4.8) | 22 (1.8) | 118 (7.8) | 18 (3.9) | 184 (4.9) | |
| Black | 40 (7.4) | 18 (1.5) | 207 (13.6) | 50 (10.7) | 315 (8.4) | |
| White, non-Hispanic | 382 (70.7) | 1083 (88.7) | 915 (60.3) | 328 (70.2) | 2708 (72.3) | |
| White, Hispanic | 38 (7.0) | 37 (3.0) | 170 (11.2) | 44 (9.4) | 289 (7.7) | |
| Unknown/other‡ | 54 (10) | 61 (5.0) | 108 (7.1) | 27 (5.8) | 250 (6.7) | |
| HCT-CI, n (%) | .20∗ | |||||
| ≥3 | 281 (52.0) | 670 (54.9) | 774 (51.0) | 263 (56.3) | 1988 (53.1) | |
| Donor characteristics | ||||||
| Donor age, y | <.01† | |||||
| Mean (SD) | 60.2 (5.65) | 26.2 (4.14) | 28.1 (4.50) | 26.5 (4.02) | 31.9 (12.5) | |
| Donor sex, n (%) | <.01∗ | |||||
| Male | 283 (52.4) | 822 (67.3) | 947 (62.4) | 261 (55.9) | 2313 (61.7) | |
| Female | 257 (47.6) | 399 (32.7) | 571 (37.6) | 206 (44.1) | 1433 (38.3) | |
| Donor/recipient CMV serostatus n (%) | <.01∗ | |||||
| +/+ | 249 (46.1) | 335 (27.4) | 563 (37.1) | 143 (30.6) | 1290 (34.4) | |
| +/− | 56 (10.4) | 117 (9.6) | 81 (5.3) | 72 (15.4) | 326 (8.7) | |
| −/+ | 118 (21.9) | 416 (34.1) | 475 (31.3) | 143 (30.6) | 1152 (30.8) | |
| −/− | 110 (20.4) | 348 (28.5) | 390 (25.7) | 109 (23.3) | 957 (25.5) | |
| Not reported | 7 (1.3) | 5 (0.4) | 9 (0.6) | 0 (0.0) | 21 (0.6) | |
| Disease characteristics | ||||||
| Primary disease, n (%) | <.01∗ | |||||
| AML | 329 (60.9) | 662 (54.2) | 857 (56.5) | 283 (60.6) | 2131 (56.9) | |
| ALL | 50 (9.3) | 119 (9.7) | 211 (13.9) | 61 (13.1) | 441 (11.8) | |
| MDS | 161 (29.8) | 440 (36.0) | 450 (29.6) | 123 (26.3) | 1174 (31.3) | |
| AML: ELN 2017 risk, n (%) | <.01∗ | |||||
| Normal | 51 (15.5) | 105 (15.9) | 154 (18.0) | 41 (14.5) | 351 (16.5) | |
| Favorable | 26 (7.9) | 86 (13.0) | 118 (13.8) | 20 (7.1) | 250 (11.7) | |
| Intermediate | 111 (33.7) | 164 (24.8) | 227 (26.5) | 73 (25.8) | 575 (27.0) | |
| Poor | 128 (38.9) | 296 (44.7) | 341 (39.8) | 143 (50.5) | 908 (42.6) | |
| APL | 0 (0.0) | 2 (0.3) | 3 (0.4) | 1 (0.4) | 6 (0.3) | |
| Not reported | 13 (4.0) | 9 (1.4) | 14 (1.6) | 5 (1.8) | 41 (1.9) | |
| ALL: cytogenetics, n (%) | .77∗ | |||||
| Normal | 6 (12.0) | 23 (19.3) | 45 (21.3) | 8 (13.1) | 82 (18.6) | |
| Poor | 37 (74.0) | 80 (67.2) | 131 (62.1) | 44 (72.1) | 292 (66.2) | |
| Other | 4 (8.0) | 12 (10.1) | 23 (10.9) | 6 (9.8) | 45 (10.2) | |
| Not reported | 3 (6.0) | 4 (3.4) | 12 (5.7) | 3 (4.9) | 22 (5.0) | |
| MDS: IPSS-R, n (%) | .55∗ | |||||
| Very low | 3 (1.9) | 8 (1.8) | 5 (1.1) | 1 (0.8) | 17 (1.4) | |
| Low | 110 (68.3) | 276 (62.7) | 287 (63.8) | 79 (64.2) | 752 (64.1) | |
| Intermediate | 11 (6.8) | 33 (7.5) | 49 (10.9) | 12 (9.8) | 105 (8.9) | |
| High | 5 (3.1) | 11 (2.5) | 16 (3.6) | 5 (4.1) | 37 (3.2) | |
| Very high | 28 (17.4) | 108 (24.5) | 88 (19.6) | 25 (20.3) | 249 (21.2) | |
| Not reported | 4 (2.5) | 4 (0.9) | 5 (1.1) | 1 (0.8) | 14 (1.2) | |
| Leukemia remission status, n (%) | <.01∗ | |||||
| First complete remission | 268 (70.7) | 613 (78.5) | 787 (73.7) | 260 (75.6) | 1928 (75.0) | |
| Second complete remission | 52 (13.7) | 79 (10.1) | 152 (14.2) | 45 (13.1) | 328 (12.8) | |
| Primary induction failure | 37 (9.8) | 61 (7.8) | 98 (9.2) | 24 (7.0) | 220 (8.6) | |
| Other§ | 22 (5.8) | 28 (3.6) | 31 (3) | 15 (4.4) | 96 (3.6) | |
| MDS remission status, n (%) | .08∗ | |||||
| No response/stable disease | 101 (62.7) | 267 (60.7) | 293 (65.1) | 65 (52.8) | 726 (61.8) | |
| Hematologic improvement | 25 (15.5) | 80 (18.2) | 69 (15.3) | 23 (18.7) | 197 (16.8) | |
| Complete remission | 25 (15.5) | 73 (16.6) | 64 (14.2) | 26 (21.1) | 188 (16.0) | |
| Other|| | 10 (6.2) | 20 (4.5) | 24 (5.4) | 9 (7.3) | 63 (5.4) | |
| Transplant characteristics | ||||||
| Graft type, n (%) | <.01∗ | |||||
| Bone marrow | 57 (10.6) | 115 (9.4) | 322 (21.2) | 79 (16.9) | 573 (15.3) | |
| Peripheral blood | 483 (89.4) | 1106 (90.6) | 1196 (78.8) | 388 (83.1) | 3173 (84.7) | |
| Time from diagnosis to transplant, d | <.01† | |||||
| Median (25-75 percentile) | 162 (113-294) | 186 (136-293) | 188 (133-323) | 199 (144-337) | 186 (133-312) | |
| GVHD prophylaxis, n (%) | <.01∗ | |||||
| PTCy + other(s) | 499 (92.4) | 1178 (96.5) | 1516 (99.9) | 464 (99.4) | 3657 (97.6) | |
| PTCy alone | 41 (7.6) | 43 (3.5) | 2 (0.1) | 3 (0.6) | 89 (2.4) | |
| Conditioning regimen intensity, n (%) | <.01∗ | |||||
| Myeloablative | 242 (44.8) | 438 (35.9) | 457 (30.1) | 136 (29.1) | 1273 (34.0) | |
| Reduced intensity | 206 (38.1) | 614 (50.3) | 396 (26.1) | 203 (43.5) | 1419 (37.9) | |
| Nonmyeloablative | 92 (17.0) | 168 (13.8) | 665 (43.8) | 127 (27.2) | 1052 (28.1) | |
| Unknown | 0 (0.0) | 1 (0.1) | 0 (0.0) | 1 (0.2) | 2 (<0.1) | |
| Transplant years, n (%) | <.01∗ | |||||
| 2014-2017 | 175 (32.4) | 175 (14.3) | 415 (27.3) | 80 (17.1) | 845 (22.6) | |
| 2018-2021 | 365 (67.6) | 1046 (85.7) | 1103 (72.7) | 387 (82.9) | 2901 (77.4) | |
| Follow-up of survivors, median (range), mo | 36 (3-101) | 26 (3-100) | 36 (3-104) | 27 (3-89) | 36 (3-104) |
APL, acute promyelocytic leukemia; CMV, cytomegalovirus; IPSS-R, revised International Prognostic Scoring System; SD, standard deviation.
Hypothesis testing: Pearson χ2 test.
Hypothesis testing: Kruskal-Wallis test.
Other race/ethnicity includes Native Hawaiian/Pacific Islander, American Indian/Alaska native, and multiple race.
Other leukemia remission includes first or higher relapse, third or higher complete remission, and not reported.
Other MDS remission status includes progression from hematologic improvement, relapse from complete remission, and not reported.